Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Empagliflozin in hypertrophic cardiomyopathy
2024-517643-31-00Phase 3Completed
- Sponsor
- National Institute of Cardiology
- Start
- Jun 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in hypertrophic cardiomyopathy (HCM) comparing Empagliflozin with Placebo (2 arms). Primary endpoints: VO2 max at 12 months and KCCQ-OS at 12 months. Started Jun 2022; status: completed.
02
Drugs
empagliflozin
03
Conditions
hypertrophic cardiomyopathy (HCM)
Beyond the preview
Go deeper on 2024-517643-31-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-517643-31-00.